eyal

Primary and multiple secondary endpoints met
A statistically significant reduction in AKI incidence following cardiac surgery was demonstrated
First multicenter Phase 2 clinical study with an investigational drug for the prevention of AKI to meet primary endpoint
QPI-1002 appears to be well tolerated with no safety issues identified

Fremont, CA – July 27, 2017 – Today, Quark […]

FREMONT, Calif., October 14, 2016 — Quark Pharmaceuticals, Inc. today announced the launch of www.EyeActNow.com to promote public awareness and subject recruitment for a global Phase II/III clinical study evaluating QPI-1007, an investigational drug designed to stop further vision loss in patients with early diagnosis of Non-arteritic Anterior Ischemic Optic Neuropathy, or NAION.

Often referred to […]

FREMONT, Calif., Sept. 19, 2016 — Today, at the RNA Therapeutics Summit in Berlin, Germany, Quark Pharmaceuticals Inc. Chief Scientific Officer Dr. Elena Feinstein will provide an overview of Quark’s clinical and non-clinical pipelines of siRNA therapeutics focused on non-liver indications to address additional urgent unmet medical needs. RNA Therapeutics Summit is an international gathering […]

Treatment for Non-Arteritic Ischemic Optic Neuropathy is
in Phase II/III Study

FREMONT, Calif., July 28, 2016 — Quark Pharmaceuticals, Inc. (“Quark”) today announced that the United States Patent and Trademark Office (“USPTO”) has granted a key patent covering the treatment of patients suffering from non-arteritic anterior ischemic optic neuropathy (“NAION”) with the Company’s ocular neuroprotectant QPI-1007. The […]

Bengaluru, India, and Fremont, CA, June 23, 2016        

 Biocon Ltd. (BSE code: 532523, NSE: BIOCON), Asia’s premier biopharmaceutical company, and Quark Pharmaceuticals, Inc., a leader in the discovery and development of novel RNA interference (RNAi)-based therapeutics, announced today the randomization of the first patient in India in the pivotal global Phase II/III study of […]

FREMONT, Calif., May 9, 2016  — Quark Pharmaceuticals, Inc. (“Quark”) today announced a keynote address on the company’s history of oligonucleotide development will be presented at the 18TH Annual TIDES Oligonucleotide and Peptide Therapeutics Conference at 11 a.m. PDT on May 10 at the Long Beach Convention Center in Long Beach, CA. Daniel Zurr, Ph.D., […]

Pleasanton, CA, and San Francisco, CA, April 14, 2016 – Transplant Genomics Inc. (“TGI”) and Quark Pharmaceuticals, Inc. (“Quark”) today announced their joint intent to pursue a discovery and development collaboration involving the use of TGI’s TruGraf™ blood test in a Phase 3 clinical trial involving patients being treated for delayed graft function (DGF) with […]

Clinical Advances with Treatments for Delayed Graft Function (DGF), Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and Acute Kidney Injury (AKI) Catapult Quark Into Front Line of siRNA Companies

FREMONT, Calif., March 14, 2016 /PRNewswire/ — Quark Pharmaceuticals Inc., a late clinical-stage pharmaceutical company and leader in the discovery and development of novel RNA interference (RNAi)-based therapeutics, […]